M&A: Panning for Gold - Pharmaceutical Executive


M&A: Panning for Gold
The industry must sift through the small pharmas and biotechs that are powering the engine of drug discovery. But searching for the right partner company can be like...

Pharmaceutical Executive

As growth potential in strategic alliances becomes a more viable option for Big Pharma, midsize players are finding that they, too, can have a piece of the pie. Traditionally, companies went public. But as the industry evolves into a more complex entity with new synergies and innovative technologies, many companies now see M&A as a viable alternative to IPO. The crunch on credit will affect the deal market. Look for companies to tap alternative financing streams to continue clinical development. Whatever the tactic, these new models allow companies to be more focused on developing products—and in the end, that's what makes a robust industry.


blog comments powered by Disqus

Serialization Summit
San Diego, CA
Feb. 27-28, 2014

Advances in Aseptic Processing
San Diego, CA
Mar. 10-12, 2014

ClinTech 2014
Cambridge, MA
Mar. 11-13 2014

Investigator-Initiated and
Sponsored Research (IISR)

Philadelphia, PA
Mar. 19-20 2014

See All Conferences >>

Source: Pharmaceutical Executive,
Click here